“…prognosis), and is particularly true in the case of heart failure (11), but has been postulated also in TTS (4,12). Nevertheless, since the prevalence of malignancy in heart failure and in TTS is not low, as seen also in our cohort (11,13,14), and similarly is the prevalence of cardiovascular conditions and risk factors in oncologic patients (10), an integrated approach caring for bidirectional cardiovascular and oncologic needs appears fundamental, though frequently challenging to be pursued (15). In fact, dedicated guidelines for management of cancer patients in cardiovascular settings are lacking, and oncologic patients are often under-represented or not adequately phenotyped in cardiovascular clinical trials, and viceversa (11,13,16).…”